Vasileios J. Assikis
Expertise in
69
conditions

Dr. Vasileios J. Assikis

Oncology | Hematology
1267 Highway 54 West, Suite 4200, 
Fayetteville, GA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
69
conditions
1267 Highway 54 West, Suite 4200, 
Fayetteville, GA 

Overview

Vasileios Assikis is an Oncologist and a Hematologist practicing medicine in Fayetteville, Georgia.

Dr. Assikis is highly rated in 69 conditions, according to our data. His clinical expertise encompasses WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Adult Soft Tissue Sarcoma, and Renal Cell Carcinoma (RCC).

Dr. Assikis is board certified in American Board Of Internal Medicine - Medical Oncology. He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 5 clinical trials. Dr. Assikis is currently accepting new patients.

Specialties

Oncology
Hematology

Licenses

Internal Medicine in GA

Board Certifications

American Board Of Internal Medicine - Medical Oncology

Fellowships

University of Texas - M.D. Anderson Cancer Center, Medical Oncology, 2003

Hospital Affiliations

Piedmont Mountainside Hospital Inc
Piedmont Newnan Hospital, Inc
Piedmont Hospital, Inc
Piedmont Fayette Hospital
Northside Hospital

Languages Spoken

English
Greek
Hebrew
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Piedmont Cancer Institute, PC
1267 Highway 54 West, Suite 4200, Fayetteville, GA 30214

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer
Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: Ascorbic acid, Paclitaxel protein-bound, Cisplatin, Gemcitabine
Study Phase: Phase 1/Phase 2
Atorvastatin in Triple-Negative Breast Cancer (TNBC) Patients Who Did Not Achieve a Pathologic Complete Response (pCR) After Receiving Neoadjuvant Chemotherapy, a Multicenter Pilot Study
Atorvastatin in Triple-Negative Breast Cancer (TNBC) Patients Who Did Not Achieve a Pathologic Complete Response (pCR) After Receiving Neoadjuvant Chemotherapy, a Multicenter Pilot Study
Enrollment Status: Terminated
Publish Date: October 02, 2024
Intervention Type: Drug
Study Drugs: Atorvastatin, Capecitabine
Study Phase: Phase 2
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer
Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer
Enrollment Status: Withdrawn
Publish Date: May 30, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

3 Total Publications

TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 22, 2021
Similar Doctors
Expertise in
5
conditions
Dr. Carlton D. Dampier
Hematology | Oncology
Expertise in
5
conditions
Dr. Carlton D. Dampier
Hematology | Oncology
Referral may be required

Children's Healthcare Of Atlanta At Hughes Spalding

35 Jesse Hill Jr Dr SE, 
Atlanta, GA 
 (19.2 miles away)
404-785-9800
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Carlton Dampier is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Dampier is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Dampier is currently accepting new patients.

Expertise in
9
conditions
Dr. Lakshmanan Krishnamurti
Hematology | Oncology
Expertise in
9
conditions
Dr. Lakshmanan Krishnamurti
Hematology | Oncology
Referral may be required

Egleston Children's Hospital At Emory

1405 Clifton Rd NE, 
Atlanta, GA 
 (23.0 miles away)
404-785-1112
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lakshmanan Krishnamurti is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Krishnamurti is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Anemia, and Bone Marrow Transplant. Dr. Krishnamurti is currently accepting new patients.

Expertise in
9
conditions
Dr. Tobey J. Macdonald
Hematology | Oncology
Expertise in
9
conditions
Dr. Tobey J. Macdonald
Hematology | Oncology
Referral may be required

Office

1760 Haygood Dr NE, 
Atlanta, GA 
 (23.1 miles away)
404-785-1112
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Tobey Macdonald is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Macdonald is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Brain Tumor, Embryonal Tumor with Multilayered Rosettes, and Posterior Fossa Tumor. Dr. Macdonald is currently accepting new patients.

Frequently Asked Questions about Dr. Vasileios J. Assikis

How do I make an appointment with Dr. Vasileios J. Assikis?

You can book an appointment with Dr. Vasileios J. Assikis by calling their office at 678-829-1060. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vasileios J. Assikis a top-rated expert for WT1-Related Wilms Tumor Syndromes?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vasileios J. Assikis is classified as an Distinguished expert for WT1-Related Wilms Tumor Syndromes, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vasileios J. Assikis specialize in?

While Dr. Vasileios J. Assikis is a Oncology, they have specific expertise in WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, and Adult Soft Tissue Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Vasileios J. Assikis participate in research or clinical trials?

Yes. Dr. Vasileios J. Assikis has published 3 articles and abstracts on conditions like WT1-Related Wilms Tumor Syndromes. You can view a list of Dr. Vasileios J. Assikis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vasileios J. Assikis accept my insurance?

Dr. Vasileios J. Assikis accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 678-829-1060 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Assikis's expertise for a condition
ConditionClose
    View All 17 Distinguished Conditions
    View All 52 Advanced Conditions
    View All 113 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile